Monitor upcoming MICVO data readouts in Fall 2026 (monotherapy Phase 1) and Q4 2026 (combination Phase 1/2) — these are the primary catalysts. The leadership transition is neutral and removes interim uncertainty.
Price Chart
Executive Summary
Pyxis Oncology appointed interim CEO Thomas Civik as permanent CEO and Chairman, replacing John Flavin who becomes Lead Independent Director. Board member Dr. Santhosh Palani resigned. The filing is a routine leadership transition with no material financial data — the company remains a clinical-stage biotech awaiting key MICVO data readouts in Fall 2026 and Q4 2026.
Key Facts
- Thomas Civik appointed permanent CEO and Chairman, effective September 4, 2026, after serving as interim CEO since February 2, 2026.
- John Flavin transitions from Chairman to Lead Independent Director and Chair of Compensation Committee.
- Dr. Santhosh Palani resigned from the Board effective September 4, 2026, citing increased time commitments; Board reduced from 8 to 7 members.
- Civik receives $710,000 annual base salary, 60% target bonus, $100,000 sign-on bonus, and a nonqualified stock option for 2,503,050 shares.
- Company expects to report updated MICVO Phase 1 monotherapy data in Fall 2026 and Phase 1/2 combination data with pembrolizumab in Q4 2026.
Financial Impact
No financial results reported. CEO compensation: $710k salary, 60% target bonus, $100k sign-on bonus, option grant for 2,503,050 shares.
Risk Factors
- Clinical-stage biotech with no approved products — MICVO data readouts are binary events.
- CEO/Chairman role combination reduces independent board oversight, though Lead Independent Director position was established.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-384386 |
| Document: pyxs-ex99_1.htm | 0001193125-26-384386 |
| Document: 0001193125-26-384386-index-headers.html | 0001193125-26-384386 |
| Document: 0001193125-26-384386-index.html | 0001193125-26-384386 |
| Document: 0001193125-26-384386.txt | 0001193125-26-384386 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $2.19 (−35.21%) |
Sep 8, 2026 24d ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $2.19 (−43.70%) |
Aug 28, 2026 5w ago | EFFECT | $3.23 $3.89 | ▼ −20.43% | ▼ −20.32% | $2.19 (+32.20%) |
Aug 13, 2026 7w ago | 8-K | $3.01 $3.12 | ▲ +3.65% | ▲ +5.62% | $2.19 (−27.24%) |
Jul 2, 2026 13w ago | 8-K | $2.63 $2.64 | ▲ +0.38% | ▼ −0.55% | $2.19 (−16.73%) |
Jun 30, 2026 13w ago | 144 | $2.85 $3.07 | ▲ +7.72% | ▲ +7.46% | $2.19 (−23.16%) |
Jun 30, 2026 13w ago | Press Release | $3.01 $2.46 | ▼ −18.27% | ▼ −18.88% | $2.19 (−27.24%) |
May 14, 2026 20w ago | 8-K | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
May 14, 2026 20w ago | Press Release | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.19 (−0.90%) |
Apr 30, 2026 22w ago | DEFA14A | $1.70 $2.26 | ▲ +32.94% | ▲ +31.21% | $2.19 (+28.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access